New combo attack on untreatable liver cancer shows promise in early trial

NCT ID NCT07685535

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase II trial is testing whether a combination of treatments can help people with a type of liver cancer that cannot be removed by surgery. The approach uses local chemotherapy delivered directly to the liver, along with immunotherapy (toripalimab) and a targeted therapy pill (lenvatinib). The study includes about 29 adults aged 18 to 85 with confirmed intrahepatic cholangiocarcinoma that has not spread to distant organs. Researchers are measuring how many patients respond, how long they live without the cancer growing, and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
toripalimab, lenvatinib, gemcitabine
What this could lead to
If successful, this combination could offer a new treatment option for people with liver cancer that cannot be surgically removed, potentially shrinking tumors and extending survival.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply to everyone. The combination of treatments may cause significant side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.